China Shineway Pharmaceutical Group (FRA:C1S) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C1S China Shineway Pharmaceutical Group Ltd FRA:C1S
92 GF Score
Price €0.86
GF Value €0.73
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is China Shineway Pharmaceutical Group FFO?

FFO (Funds from operations) only applies to REITs.

FRA:C1S
92GF Score
China Shineway Pharmaceutical Group Ltd FRA:C1S
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Shineway Pharmaceutical Group (FRA:C1S) Overvalued in 2026?

Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued. The current stock price of €0.86 is trading 17.8% above its estimated GF Value™ of €0.73. GuruFocus considers China Shineway Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for FRA:C1S:

  • FFO:
  • GF Value™: €0.73 vs. price of €0.86 (17.8% above fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the FRA:C1S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Shineway Pharmaceutical Group Business Description

Other Exchanges 02877:Hong KongC1S:Germany
Address Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score

Get the complete analysis for FRA:C1S

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€0.73
GF Value